Incremental yield of genome sequencing after exome sequencing for nonimmune hydrops fetalis spectrum.

Authors

Rozlyn Ct Boutin, Billie R Lianoglou, Nuriye N Sahin Hodoglugil, Katie Tick, Carmen Ma Santoli, Ugur Hodoglugil, Pierre Martin, Jessica Van Ziffle, Patrick Devine, Neil Risch, Mary E Norton, Teresa N Sparks

Published in

American journal of obstetrics & gynecology MFM. Pages 102067. Jul 18, 2026. Epub Jul 18, 2026.

Abstract

Exome sequencing (ES) detects a monogenic disorder in approximately 30% of pregnancies with unexplained nonimmune hydrops fetalis spectrum (NIHFS), i.e. those with NIHF or single pathologic fetal fluid collections. Because genome sequencing (GS) can identify additional genetic variants not detectable by ES, we sought to determine the proportion of cases with new reportable findings on GS following non-diagnostic standard of care testing including ES for NIHFS.
Cohort study of pregnancies with NIHFS that had non-diagnostic results of karyotype and/or chromosomal microarray (CMA) and ES. Eligible fetal fluid collections included at least one of: ascites, pleural or pericardial effusions, skin edema, cystic hygroma, and/or nuchal translucency ≥ 3.5mm. Pregnancies with NIHFS that did not receive a clear diagnosis with prior testing underwent additional testing with genome sequencing (GS). ES and GS were performed in a CLIA-approved laboratory, and genetic variants were classified according to the American College of Medical Genetics and Genomics guidelines. Primary outcome was the proportion of new reportable pathogenic or likely pathogenic (P/LP) variants identified on GS and resulting in a new diagnosis. Secondary outcome was the incremental yield of GS for detecting new secondary findings and variants of uncertain significance (VUSs).
Overall, 118 fetal samples underwent GS following negative (n=102) or inconclusive (n=16) ES. GS identified four P/LP copy number variants previously not detected by karyotype, CMA, or ES that led to a new genetic diagnosis in three pregnancies, providing a new positive finding yield of 2.5% (3/118). Additionally, one secondary finding and four VUSs were identified by GS in four different pregnancies. In contrast to the primary outcome, these additional findings were largely the result of updated analytical tools and literature rather than GS-specific technology.
GS has a small but clinically relevant increased diagnostic yield over chromosome studies and ES for NIHFS, particularly for identifying copy number variants. As interpretation of noncoding regions and complex genomic variations improves, the incremental positive finding yield of GS is expected to further increase.

PMID:
42471198
Bibliographic data and abstract were imported from PubMed on 19 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.